lymphoma is a broad category of hematologic malignancies characterized by the abnormal, uncontrolled proliferation of lymphocytes (B cells, T cells, or natural killer cells) within the lymphatic system. It is primarily distinguished from leukemia, which typically originates in the bone marrow and presents with circulating tumor cells in the blood, whereas lymphoma typically presents as solid tumors within lymphoid tissues (such as lymph nodes, spleen, or thymus). The underlying pathological mechanism involves genetic mutations (often chromosomal translocations) in lymphocytes that arrest their normal development and apoptosis, leading to clonal expansion. Lymphomas are strictly pathological and are broadly divided into two main clinically relevant subtypes: Hodgkin lymphoma (C81.-), characterized by the presence of multinucleated Reed-Sternberg cells, and Non-Hodgkin lymphoma (C82.- through C85.-), which encompasses a vast, heterogeneous group of B-cell and T-cell neoplasms. It is commonly confused with metastatic carcinoma to the lymph nodes; however, lymphoma is a primary cancer of the lymphatic tissue itself, not a secondary spread from a solid organ tumor.
The word entered English in the 1830s as lymphoma (noun), coined from the Latin root lympha and the Greek suffix -oma — literally “tumor of the lymph.” The root lymph- (“clear fluid/water”) connects lymphoma to the entire lymph- ROOT FAMILY: lymphadenopathy (disease of the lymph nodes), lymphocyte (lymph cell), and lymphedema (swelling due to lymph fluid). The suffix -oma is highly productive in medical oncology terminology, appearing in numerous terms such as carcinoma, sarcoma, and melanoma.
🔀 ALIASES / ALTERNATE TERMS
Lymphomatous(adjective form — e.g., “lymphomatous involvement,” “lymphomatous mass”)
Lymphatic cancer(lay term; commonly used in patient education and general oncology settings)
Hodgkin’s Disease(historical clinical synonym; now formally termed Hodgkin Lymphoma)
NHL(clinical acronym for Non-Hodgkin Lymphoma, the most common broad category)
B-cell Lymphoma(cellular subtype; accounts for the vast majority of NHL cases, e.g., Diffuse Large B-Cell Lymphoma)
T-cell Lymphoma(cellular subtype; less common, often presenting with cutaneous or systemic involvement)
Lymphosarcoma(historical/obsolete term for non-Hodgkin lymphoma; rarely used in modern pathology)
Extranodal Lymphoma(anatomic subtype; lymphoma presenting outside of the lymph nodes, such as in the stomach, CNS, or skin)
Mycosis Fungoides(specific clinical entity; the most common type of cutaneous T-cell lymphoma; C84.0-)
🔗 RELATED TERMS
Leukemia — a closely related hematologic malignancy; originates primarily in the bone marrow and blood rather than forming solid lymphatic masses, though mature B-cell neoplasms can blur this line (e.g., CLL/SLL).
Lymphadenopathy — shares the lymph- root; refers to enlarged lymph nodes, which is the most common presenting symptom of lymphoma but is most often benign/reactive.
Multiple Myeloma — a distinct hematologic malignancy of plasma cells (terminally differentiated B cells) that primarily causes bone lesions and marrow failure (C90.0-).
Metastatic Carcinoma — cancer that has spread to the lymph nodes from a primary solid organ site (e.g., breast, lung); distinct from lymphoma, which is primary to the node.
Clonal Expansion — the cellular mechanism underlying lymphoma, where a single mutated lymphocyte replicates uncontrollably to form the tumor mass.
Reed-Sternberg Cell — the hallmark diagnostic, multinucleated giant cell required for the diagnosis of classic Hodgkin lymphoma.
Waldeyer’s Ring — an anatomic ring of lymphoid tissue in the pharynx (tonsils, adenoids) that is a common site for extranodal lymphoma presentation.
Epstein-Barr Virus (EBV) — an oncogenic virus strongly associated with the development of certain lymphomas, particularly Burkitt lymphoma and Hodgkin lymphoma (B27.-).
Excisional Lymph Node Biopsy — the primary diagnostic procedure required for definitive lymphoma diagnosis and subtyping, as fine needle aspiration (FNA) often destroys necessary tissue architecture.
Splenectomy; total (en bloc for extensive disease or diagnostic purposes)
⚠️ Coding Note:Inpatient profee coding for lymphoma requires strict attention to the 5th character of the ICD-10-CM code, which dictates the specific lymph node region or extranodal site involved (e.g., 1=head/neck, 8=multiple sites, 9=extranodal). Unlike leukemia codes, lymphoma codes do not have a 6th character to indicate “in remission.” If a provider documents “lymphoma in remission,” you must query to determine if the patient is still receiving active surveillance/treatment (code the active malignancy) or if treatment is complete with no evidence of disease (code Z85.7-, Personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues). A common undercoding error occurs when providers document “lymphadenopathy” or “mass” on the discharge summary while the pathology report confirms “Diffuse Large B-Cell Lymphoma”; always query to link the pathology findings to the final diagnosis for accurate HCC capture. For Noridian MAC jurisdictions, ensure highly specific subtyping (e.g., Mantle Cell vs. DLBCL) is documented, as prior authorizations for advanced therapies like CAR-T cell infusions or targeted biologics are strictly tied to the exact histological subtype.